The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwNHL 2019 | Possibilities for the use of pembrolizumab in lymphoma treatment
John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, ON, Canada, speaking at the 17th International Workshop on Non-Hodgkin Lymphoma, Boston, MA, discusses the use of pembrolizumab in the treatment of varying lymphomas. Dr Kuruvilla discusses the parallels between Hodgkin lymphoma and primary mediastinal lymphoma, and suggests an increase in usage of the drug as treatment for Richter transformation, CNS disease, and testicular involvement.
